Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

Prostate cancer is the second-leading cause of cancer-related mortality in men in Western societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. Although a majority of patients initially respond to ADT, most will eventually develop castrate resistance, defined as disease progression despite serum testosterone levels of

• NI
  National Institutes of Health

  Awards: 5 P30 CA016672, CA016672, P30 CA016672
• UO
  University of Texas MD Anderson Cancer Center

  Awards: 5 P30 CA016672, CA016672, P30 CA016672